Industry must step up to tackle AMR threat
Generics manufacturers must “step up” to tackle antimicrobial resistance (AMR), the Access to Medicine Foundation has insisted, in a report that “systematically evaluates how a cross-section of the pharmaceutical industry is responding to the AMR threat”.
You may also be interested in...
Generics firms have a crucial role to play in the fight against antimicrobial resistance, Thomas Cueni, chair of the AMR Industry Alliance, tells Generics Bulletin in an exclusive interview.
Alvogen can sell in the US generic lenalidomide on a volume-limited basis after March 2022, and without volume limitations in early 2026, after settling patent litigation with Celgene relating to the originator’s Revlimid. Dr Reddy's has also settled in Canada.
Alvogen’s Lotus subsidiary and Cambrex are expanding their manufacturing capabilities in Taiwan and Canada respectively. As several firms reveal the results of FDA inspections, the agency slaps United Exchange Corporation with a warning letter.